Cargando…
Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
BACKGROUND: Myxomatous mitral valve degeneration (MMVD) is the most common degenerative heart disease in dogs and is associated with irreversible changes in the valve tissue. Although traditional cardiac biomarkers are efficient for diagnosing MMVD, there are limitations, therefore, it is important...
Autores principales: | Kim, Hyeon-Jin, Kim, Jihyun, Kim, Soomin, Kim, Ha-Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990206/ https://www.ncbi.nlm.nih.gov/pubmed/36882760 http://dx.doi.org/10.1186/s12917-023-03583-7 |
Ejemplares similares
-
Myxomatous degeneration of the mitral valve
por: Neto, Felippe Lazar, et al.
Publicado: (2018) -
Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration
por: Tan, Karen, et al.
Publicado: (2019) -
Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling
por: van Nieuwenhoven, Frans A., et al.
Publicado: (2017) -
Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease
por: Menciotti, Giulio, et al.
Publicado: (2017) -
Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease
por: Li, Qinghong, et al.
Publicado: (2015)